Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.31 USD
+0.03 (2.34%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CLSD 1.31 +0.03(2.34%)
Will CLSD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Other News for CLSD
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Buy Rating for Clearside Biomedical’s CLS-AX Based on Superior Efficacy and Market Adoption Potential
Clearside Biomedical management to meet with Oppenheimer
Clearside Biomedical’s CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target